Allogene Therapeutics Inc (NASDAQ:ALLO) – Analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for shares of Allogene Therapeutics in a research note issued on Monday, March 11th. Jefferies Financial Group analyst B. Amin forecasts that the company will post earnings of ($0.39) per share for the quarter. Jefferies Financial Group also issued estimates for Allogene Therapeutics’ Q2 2019 earnings at ($0.50) EPS, Q3 2019 earnings at ($0.54) EPS, Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($2.04) EPS, FY2020 earnings at ($2.28) EPS, FY2021 earnings at ($2.59) EPS, FY2022 earnings at ($3.02) EPS and FY2023 earnings at ($2.51) EPS.
Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10).
Shares of ALLO opened at $26.74 on Thursday. Allogene Therapeutics has a 12-month low of $21.67 and a 12-month high of $35.55. The firm has a market cap of $3.22 billion and a P/E ratio of -4.06.
Hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new stake in Allogene Therapeutics in the fourth quarter valued at $156,000. Creative Planning bought a new stake in Allogene Therapeutics in the fourth quarter valued at $544,000. VV Manager LLC bought a new stake in Allogene Therapeutics in the fourth quarter valued at $206,853,000. Artal Group S.A. bought a new stake in Allogene Therapeutics in the fourth quarter valued at $10,772,000. Finally, Shikiar Asset Management Inc. bought a new stake in Allogene Therapeutics in the fourth quarter valued at $1,056,000. Institutional investors own 44.94% of the company’s stock.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.
Featured Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.